HighQC™ Human IPSC From LCL-Breast Cancer

Description

HighQC™ Human IPSC From LCL-Breast Cancer is a disease-specific human induced pluripotent stem cell line. It was generated by reprogramming a lymphoblastoid cell line (LCL) derived from peripheral blood mononuclear cells (PBMCs) of a donor with breast cancer. The reprogramming was performed using non-integrating episomal plasmid method. The resulting breast cancer patient-derived iPSCs (induced pluripotent stem cells) exhibit adherent growth with a high nucleus-to-cytoplasm ratio. They maintain pluripotency for breast cancer-related molecular mechanism studies. These cells retain the fundamental capacity for trilineage differentiation into cell types of the ectoderm, mesoderm, and endoderm germ layers. They express the core pluripotency marker SSEA-4. The cells undergo rigorous screening and isolation procedures, and are rigorously tested to ensure they are free of contamination from HIV-1, HBV, HCV, Syphilis, Mycoplasma, Fungi, Yeast, and Bacteria.